Chronic inflammatory bowel disease and cancer.

Area of Science:

• Gastroenterology and Oncology
• Inflammatory Bowel Disease (IBD) Research
• Cancer Epidemiology

Background:

• Inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn's disease (CD), significantly increases the risk of colorectal cancer (CRC).
• CRC is a major cause of mortality in IBD patients, with increased incidence observed in 5.5-13.5% of UC patients and 0.4-0.8% of CD patients.
• Established risk factors for IBD-associated CRC include disease duration, extent, low activity, young age at onset, primary sclerosing cholangitis, and inadequate surveillance.

Purpose of the Study:

• To review the epidemiology, risk factors, and management of colorectal cancer in patients with ulcerative colitis and Crohn's disease.
• To highlight the diagnostic challenges and genetic similarities between IBD-associated CRC and sporadic CRC.
• To discuss the role and recommendations for surveillance programs in the early detection of IBD-associated CRC.

Main Methods:

• Review of existing literature on colorectal cancer in ulcerative colitis and Crohn's disease.
• Analysis of risk factors, disease characteristics, and survival data.
• Evaluation of diagnostic methods, including histology, tumor markers, and genetic alterations.
• Assessment of current surveillance strategies and recommendations.

Main Results:

• IBD-associated CRC shares genetic alterations with sporadic CRC, with dysplasia being a strong indicator of malignancy.
• Tumor stage at diagnosis is the most critical prognostic factor for survival in IBD-associated CRC.
• While surveillance programs have limitations in preventing tumors, they can reduce mortality by enabling earlier cancer detection.

Conclusions:

• Colorectal cancer surveillance in IBD patients is crucial for early detection and improved outcomes.
• Biennial colonoscopies with biopsies are recommended after 8-10 years of total colitis or 15-20 years of left-sided colitis.
• Management decisions for dysplasia and cancer should be based on the grade of dysplasia and clinical presentation, with proctocolectomy considered for high-grade dysplasia or cancer.